Back to results
US 7,514,089 B2Granted
Genetically modified tumor-targeted bacteria with reduced virulence
AssigneeVion Pharmaceuticals, Inc.
InventorsDavid Bermudes, Kenneth Brooks Low
Life of this patent
Estimating the term…
Abstract
The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
Claims12
A mutant Salmonella sp. comprising a disrupted msbB gene in which the mutant Salmonella targets solid tumor when administered in vivo.
Dependencies are inferred from the claim text.